Abstract:Importance The prevalence of early-stage non–small cell lung cancer (NSCLC) is expected to increase with recent implementation of annual screening programs. Reliable prognostic biomarkers are needed to identify patients at a high risk for recurrence to guide adjuvant therapy. Objective To develop a robust, individualized immune signature that can estimate prognosis in patients with early-stage nonsquamous NSCLC. Design, Setting, and Participants This retrospective study analyzed the gene expression profiles of frozen tumor tissue samples from 19 public NSCLC cohorts, including 18 microarray data sets and 1 RNA-Seq data set for The Cancer Genome Atlas (TCGA) lung adenocarcinoma cohort. Only patients with nonsquamous NSCLC with clinical annotation were included. Samples were from 2414 patients with nonsquamous NSCLC, divided into a meta-training cohort (729 patients), meta-testing cohort (716 patients), and 3 independent validation cohorts (439, 323, and 207 patients). All patients underwent surgery with a negative surgical margin, received no adjuvant or neoadjuvant therapy, and had publicly available gene expression data and survival information. Data were collected from July 22 through September 8, 2016. Main Outcomes and Measures Overall survival. Results Of 2414 patients (1205 men [50%], 1111 women [46%], and 98 of unknown sex [4%]; median age [range], 64 [15-90] years), a prognostic immune signature of 25 gene pairs consisting of 40 unique genes was constructed using the meta-training data set. In the meta-testing and validation cohorts, the immune signature significantly stratified patients into high- vs low-risk groups in terms of overall survival across and within subpopulations with stage I, IA, IB, or II disease and remained as an independent prognostic factor in multivariate analyses (hazard ratio range, 1.72 [95% CI, 1.26-2.33; P < .001] to 2.36 [95% CI, 1.47-3.79; P < .001]) after adjusting for clinical and pathologic factors. Several biological processes, including chemotaxis, were enriched among genes in the immune signature. The percentage of neutrophil infiltration (5.6% vs 1.8%) and necrosis (4.6% vs 1.5%) was significantly higher in the high-risk immune group compared with the low-risk groups in TCGA data set (P < .003). The immune signature achieved a higher accuracy (mean concordance index [C-index], 0.64) than 2 commercialized multigene signatures (mean C-index, 0.53 and 0.61) for estimation of survival in comparable validation cohorts. When integrated with clinical characteristics such as age and stage, the composite clinical and immune signature showed improved prognostic accuracy in all validation data sets relative to molecular signatures alone (mean C-index, 0.70 vs 0.63) and another commercialized clinical-molecular signature (mean C-index, 0.68 vs 0.65). Conclusions and Relevance The proposed clinical-immune signature is a promising biomarker for estimating overall survival in nonsquamous NSCLC, including early-stage disease. Prospective studies are needed to test the clinical utility of the biomarker in individualized management of nonsquamous NSCLC.

A Quantitative CT Imaging Signature Predicts Survival and Complements Established Prognosticators in Stage I Non-Small Cell Lung Cancer

Delta Radiomics Model for the Prediction of Progression-Free Survival Time in Advanced Non-Small-cell Lung Cancer Patients after Immunotherapy.

A Robust 8-Gene Prognostic Signature for Early-Stage Non-small Cell Lung Cancer.

A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.

Non-small cell lung cancer: quantitative phenotypic analysis of CT images as a potential marker of prognosis

Identification and Validation of a Radiomic Signature for Predicting Survival Outcomes in Non-Small-cell Lung Cancer Treated with Radiation Therapy

Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non–Small Cell Lung Cancer

CT-based radiomics signatures can predict the tumor response of non-small cell lung cancer patients treated with first-line chemotherapy and targeted therapy

CT-derived radiomic analysis for predicting the survival rate of patients with non-small cell lung cancer receiving radiotherapy

Development of a Radiomics Nomogram Based on the 2D and 3D CT Features to Predict the Survival of Non-Small Cell Lung Cancer Patients

Fusion of Quantitative Image and Genomic Biomarkers to Improve Prognosis Assessment of Early Stage Lung Cancer Patients

Radiomics Signature Predicts the Recurrence-Free Survival in Stage I Non-Small Cell Lung Cancer

CT-based radiomics signature to predict CD8+ tumor infiltrating lymphocytes in non-small-cell lung cancer

Identification of a Immune-Related Genes Signature for Survival Prediction in Stage I Lung Adenocarcinoma

An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scans

Risk stratification and overall survival prediction in extensive stage small cell lung cancer after chemotherapy with immunotherapy based on CT radiomics

Exploring New Quantitative CT Image Features to Improve Assessment of Lung Cancer Prognosis.

Radiomics for Survival Risk Stratification of Clinical and Pathologic Stage IA Pure-Solid Non–Small Cell Lung Cancer

Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer

Radiomics Signature: A Potential and Incremental Predictor for EGFR Mutation Status in NSCLC Patients, Comparison with CT Morphology.

A Robust Six-Gene Prognostic Signature for Prediction of Both Disease-Free and Overall Survival in Non-Small Cell Lung Cancer